MPM Asset Management’s Entrada Therapeutics TRDA Stock Holding History

MPM Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$25.4M	Hold	4,381,062	–	–	57.09%	1
2025 Q2	$29.4M	Hold	4,381,062	–	–	67.92%	1
2025 Q1	$39.6M	Hold	4,381,062	–	–	57.04%	1
2024 Q4	$75.7M	Sell	4,381,062 -44,722	-1%	-$810K	60.89%	1
2024 Q3	$70.7M	Hold	4,425,784	–	–	48.68%	1
2024 Q2	$63.1M	Hold	4,425,784	–	–	34.64%	1
2024 Q1	$62.7M	Hold	4,425,784	–	–	25.58%	2
2023 Q4	$66.8M	Hold	4,425,784	–	–	32.82%	1
2023 Q3	$69.9M	Hold	4,425,784	–	–	37.45%	1
2023 Q2	$67M	Hold	4,425,784	–	–	32.86%	1
2023 Q1	$64.2M	Hold	4,425,784	–	–	26.74%	1
2022 Q4	$59.8M	Hold	4,425,784	–	–	25.04%	1
2022 Q3	$69.8M	Hold	4,425,784	–	–	26.57%	1
2022 Q2	$53.9M	Hold	4,425,784	–	–	22.75%	2
2022 Q1	$41.6M	Hold	4,425,784	–	–	14.2%	3
2021 Q4	$75.8M	Buy	+4,425,784	New	+$107M	16.37%	2

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MPM Asset Management's TRDA Position: Q3 2025 in Review

MPM Asset Management held its Entrada Therapeutics (TRDA) position steady in Q3 2025 at 4,381,062 shares worth $25.4M. The position accounts for 57.09% of the portfolio, ranked #1.

MPM Asset Management first reported a position in TRDA in Q4 2021 and has held it in 16 quarters since. The position peaked at $75.8M in Q4 2021. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

MPM Asset Management held 4,381,062 shares of Entrada Therapeutics worth $25.4M as of Q3 2025.
MPM Asset Management left its Entrada Therapeutics share count unchanged in Q3 2025.
Entrada Therapeutics made up 57.09% of MPM Asset Management's portfolio in Q3 2025, its #1 holding.
MPM Asset Management first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 16 quarters since.
MPM Asset Management's Entrada Therapeutics position peaked at $75.8M in Q4 2021.
117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on MPM Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.